GA NCORP

Doctors

Stephen J. Ramey MD

Nancy N. and J.C. Lewis Cancer and Research Pavilion at St. Joseph's/Candler
www.sjchs.org

Education & Training

Medical School: Medical University of South Carolina, Charleston, SC

Internship: Medical University of South Carolina, Charleston, SC

Residency: University of Miami/Jackson Memorial Hospital, Miami, FL

Specialty and Certification

Radiation Oncology / Board Certified

Clinical Trial Cancer Types

Brain & Spinal Cord Tumor, Breast Cancer, Cancer-Related Syndrome, Cervical Cancer, Esophogeal Cancer, Gynecologic Cancers, Head and Neck Cancer, Hematopoietic Malignancies, Leukemia, Lung Cancer, Myelodysplastic Syndromes (MDS), Prostate Cancer , Quality of Life, Solid Tumor, Uterine Cancer

Affliations

St. Joseph's/Candler

Active Clinical Trial Sites


Nancy N. and J.C. Lewis Cancer Research Pavilion at St. Joseph Candler

225 Candler Drive
Savannah, GA 31405
912-819-5704 (p)
www.sjchs.org

driving directions

Clinical Trials

Testing Ramipril to Prevent Memory Loss in People with Glioblastoma
Cancer Type: Brain & Spinal Cord Tumor

Testing the Use of the Immunotherapy Drugs Ipilimumab and Nivolumab plus Radiation Therapy Compared to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed MGMT Unmethylated Glioblastoma
Cancer Type: Brain & Spinal Cord Tumor

Regional Radiation Therapy with or without Whole Breast Irradiation in Treating Patients with Estrogen Receptor Positive, HER2 Negative Low Risk Breast Cancer Who Have Undergone Breast Conserving Surgery or Mastectomy
Cancer Type: Breast Cancer

Radiation Therapy with or without Olaparib in Treating Patients with Inflammatory Breast Cancer
Cancer Type: Breast Cancer

An Internet-based Program to Help Cancer Survivors Manage Pain (IMPACTS)
Cancer Type: Cancer Control

Tissue Collection and Natural History Study of Patients with Myelodysplastic Syndrome or Myeloproliferative Neoplasms
Cancer Type: Cancer-Related Syndrome

Testing the Addition of a New Anti-Cancer Drug, Triapine, to the Usual Chemotherapy Treatment (Cisplatin) during Radiation Therapy for Advanced-stage Cervical and Vaginal Cancers
Cancer Type: Cervical Cancer

Nivolumab and Ipilimumab in Treating Patients with Esophageal and Gastroesophageal Junction Adenocarcinoma Undergoing Surgery
Cancer Type: Esophogeal Cancer

Testing the Addition of a New Anti-Cancer Drug, Triapine, to the Usual Chemotherapy Treatment (Cisplatin) during Radiation Therapy for Advanced-stage Cervical and Vaginal Cancers
Cancer Type: Gynecologic Cancers

Testing Docetaxel-Cetuximab or the Addition of an Immunotherapy drug, Atezolizumab, to the Usual Chemotherapy and Radiation Therapy in High-Risk Head and Neck Cancer
Cancer Type: Head and Neck Cancer

Testing Immunotherapy versus Observation in Patients with HPV Throat Cancer
Cancer Type: Head and Neck Cancer

Smoke Free Support Study 2.0
Cancer Type: Hematopoietic Malignancies

Financial Navigation Program to Improve Understanding and Management of Financial Aspects of Cancer Care for Patients and Their Spouses
Cancer Type: Hematopoietic Malignancies

Tissue Collection and Natural History Study of Patients with Myelodysplastic Syndrome or Myeloproliferative Neoplasms
Cancer Type: Leukemia

Testing Whether Avoiding the Hippocampus During Whole-Brain Radiation Therapy Prevents Cognitive Side Effects in Patients with Small Cell Lung Cancer
Cancer Type: Lung Cancer

Testing the Addition of a New Immunotherapy Drug, Atezolizumab (MPDL3280A), to the Usual Chemoradiation (CRT) Therapy Treatment for Limited Stage Small Cell Lung Cancer (LS-SCLC)
Cancer Type: Lung Cancer

Testing the Addition of an Antibody to Standard Chemoradiation followed by the Antibody for One Year to Standard Chemoradiation followed by One Year of the Antibody in Patients with Unresectable Stage III Non-Small Cell Lung Cancer
Cancer Type: Lung Cancer

Testing Whether the Use of Brain Scans Alone Instead of Brain Scans plus Preventive Brain Radiation Affects Lifespan in Patients with Small Cell Lung Cancer
Cancer Type: Lung Cancer

Testing the Addition of Radiation Therapy to the Usual Immune Therapy Treatment (Atezolizumab) for Extensive Stage Small Cell Lung Cancer, The RAPTOR Trial
Cancer Type: Lung Cancer

Testing the Addition of the Drug Atezolizumab to the Usual Radiation Treatment for Patients with Early Non-small Cell Lung Cancer
Cancer Type: Lung Cancer

Tissue Collection and Natural History Study of Patients with Myelodysplastic Syndrome or Myeloproliferative Neoplasms
Cancer Type: Myelodysplastic Syndromes (MDS)

Antiandrogen Therapy and Radiation Therapy with or without Docetaxel in Treating Patients with Prostate Cancer That Has Been Removed by Surgery
Cancer Type: Prostate Cancer

Stereotactic Body Radiation Therapy or Intensity-Modulated Radiation Therapy in Treating Patients with Stage IIA-B Prostate Cancer
Cancer Type: Prostate Cancer

Effect of Treatment on Work Experience in Patients with Stage I-III Prostate Cancer
Cancer Type: Prostate Cancer

Use of a Clinical Screening Tool to Address Cancer Health Disparities in the NCI Community Oncology Research Program (NCORP)
Cancer Type: Quality of Life

Smoke Free Support Study 2.0
Cancer Type: Solid Tumor

Testing Docetaxel-Cetuximab or the Addition of an Immunotherapy drug, Atezolizumab, to the Usual Chemotherapy and Radiation Therapy in High-Risk Head and Neck Cancer
Cancer Type: Unknown Primary

Antiandrogen Therapy and Radiation Therapy with or without Docetaxel in Treating Patients with Prostate Cancer That Has Been Removed by Surgery
Cancer Type: Unknown Primary

Stereotactic Body Radiation Therapy or Intensity-Modulated Radiation Therapy in Treating Patients with Stage IIA-B Prostate Cancer
Cancer Type: Unknown Primary

Radiation Therapy with or without Olaparib in Treating Patients with Inflammatory Breast Cancer
Cancer Type: Unknown Primary

Testing Immunotherapy versus Observation in Patients with HPV Throat Cancer
Cancer Type: Unknown Primary

Smoke Free Support Study 2.0
Cancer Type: Unknown Primary

Effect of Treatment on Work Experience in Patients with Stage I-III Prostate Cancer
Cancer Type: Unknown Primary

Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to the Usual Radiation Treatment for Newly Diagnosed Early Stage High Intermediate Risk Endometrial Cancer
Cancer Type: Unknown Primary

Testing the Use of the Immunotherapy Drugs Ipilimumab and Nivolumab plus Radiation Therapy Compared to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed MGMT Unmethylated Glioblastoma
Cancer Type: Unknown Primary

Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to the Usual Radiation Treatment for Newly Diagnosed Early Stage High Intermediate Risk Endometrial Cancer
Cancer Type: Uterine Cancer